Suchergebnisse - (Subject:"2494G1JF75")

PubPharm (115)

1

HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

enthalten in: Antiviral research | 2022

von Foo, C. | Abdelnabi, R. | Kaptein, S. | +23

2

Positive detection of SARS-CoV-2 combined HSV1 and HHV6B virus nucleic acid in tear and conjunctival secretions of a non-conjunctivitis COVID-19 patient with obstruction of common lacrimal duct

enthalten in: Acta ophthalmologica | 2020

von Hu, Y. | Chen, T. | Liu, M. | +7

3

Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs

enthalten in: The Journal of antimicrobial chemotherapy | 2018

von Puertas, M. | Gómez-Mora, E. | Santos, J. | +11

4

Therapeutic drug monitoring of boosted PIs in HIV-positive patients : undetectable plasma concentrations and risk of virological failure

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Calcagno, A. | Pagani, N. | Ariaudo, A. | +8

5

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients

enthalten in: PloS one | 2017

von Gianotti, N. | Cozzi-Lepri, A. | Antinori, A. | +11

6

Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain

enthalten in: Journal of medical virology | 2016

von Pernas, B. | Grandal, M. | Tabernilla, A. | +7

7

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor : An Unsettled Issue

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2016

von Karris, M. | Jain, S. | Bowman, V. | +11

8

Efficacy of protease inhibitor monotherapy vs. triple therapy : meta-analysis of data from 2303 patients in 13 randomized trials

enthalten in: HIV medicine | 2016

von Arribas, J. | Girard, P. | Paton, N. | +5

9

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2015

von Arribas, J. | Girard, P. | Landman, R. | +118

CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879

10

Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials

enthalten in: HIV clinical trials | 2014

von Powderly, W. | Hill, A. | Moecklinghoff, C.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]